{
    "clinical_study": {
        "@rank": "114157", 
        "acronym": "RivaMoS2", 
        "arm_group": {
            "arm_group_label": "Observation group", 
            "description": "This group includes all volunteers of this observation study."
        }, 
        "biospec_descr": {
            "textblock": "Plasma samples for coagulation assays"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "Rivaroxaban (RXA; brand name Xarelto\u00ae) is an oral direct factor Xa inhibitor that is applied\n      for prophylaxis of venous thromboembolism (VTE) after major orthopedic surgery of the lower\n      limbs such as hip and knee replacement surgery. Additionally, RXA is approved by Swissmedic\n      to be used at a therapeutic dose for primary therapy of VTE and for prophylaxis of\n      cerebrovascular events in non-valvular atrial fibrillation.\n\n      Monitoring of RXA concentration (conc.) is generally not required because of its stable\n      pharmacokinetic and pharmacodynamic profile, even in patients with renal insufficiency.\n      However, there are several clinical situations, in which it may be desirable to measure the\n      RXA plasma conc. The range of RXA conc. is wide among individuals with typical peak levels\n      of median 244 \u00b5g/L (IQR 175-360) and trough levels of median 32 \u00b5g/L (IQR 19-60) with once\n      daily doses of 20 mg RXA.\n\n      This is an explorative laboratory study to evaluate the intra-individual variability of RXA\n      conc. in time and to standardize assays among 9 Swiss laboratories to determine RXA conc."
        }, 
        "brief_title": "Rivaroxaban Laboratory Monitoring in Switzerland 2: Therapeutic Dose (RivaMoS 2)", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Male, aged 18-65 years\n\n          -  No known comorbidity or disease\n\n          -  No known galactose intolerance, lactase deficiency or glucose galactose malabsorption\n\n          -  Taking no other medicaments\n\n          -  No history for disorders regarding hemostasis\n\n          -  Initial screening laboratory test showing normal values for liver/pancreas function\n             (ALAT,ASAT,gGT, alkalic phosphatase, bilirubin, amylase, lipase), kidney function\n             (creatinine), hematogram (white blood cell count, hemoglobin, platelet count), and\n             coagulation parameters (\"Gerinnungsstatus\" with PT, aPTT, fibrinogen, thrombin time)\n\n          -  written informed consent\n\n        Exclusion Criteria:\n\n          -  none"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Healthy male volunteers aged 18-65 years"
            }
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01710267", 
            "org_study_id": "12041"
        }, 
        "intervention": {
            "arm_group_label": "Observation group", 
            "description": "20 mg/d for 11 days", 
            "intervention_name": "Rivaroxaban", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 12, 2013", 
        "link": {
            "description": "Division of Hematology and Central Hematology Laboratory, Luzerner Kantonsspital, Switzerland", 
            "url": "https://www.luks.ch/standorte/luzern/kliniken/medizin/haematologie.html"
        }, 
        "location": {
            "contact": {
                "email": "walter.wuillemin@luks.ch", 
                "last_name": "Walter Wuillemin, MD", 
                "phone": "+41412055147"
            }, 
            "contact_backup": {
                "email": "gaby.fahrni@luks.ch", 
                "last_name": "Gaby Fahrni, RN", 
                "phone": "+41412051803"
            }, 
            "facility": {
                "address": {
                    "city": "Luzern", 
                    "country": "Switzerland", 
                    "state": "LU", 
                    "zip": "6000"
                }, 
                "name": "Luzerner Kantonsspital"
            }, 
            "investigator": {
                "last_name": "Pirmin Schmid, MD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_groups": "1", 
        "official_title": "Rivaroxaban Laboratory Monitoring in Switzerland 2: Therapeutic Dose (RivaMoS 2)", 
        "overall_contact": {
            "email": "walter.wuillemin@luks.ch", 
            "last_name": "Walter Wuillemin, MD, PhD", 
            "phone": "+41412055147"
        }, 
        "overall_contact_backup": {
            "email": "gaby.fahrni@luks.ch", 
            "last_name": "Gaby Fahrni, RN", 
            "phone": "+41412051803"
        }, 
        "overall_official": {
            "affiliation": "Luzerner Kantonsspital", 
            "last_name": "Walter A Wuillemin, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Evaluation of the effect of RXA on trough and peak RXA conc. values in time", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01710267"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Luzerner Kantonsspital", 
            "investigator_full_name": "Prof. Dr. Dr. med. Walter A. Wuillemin, MD, PhD", 
            "investigator_title": "Chief, Division of Hematology and Central Hematology Laboratory, Luzerner Kantonsspital, Switzerland", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "coagulation assays such as PT, PTT, individual coagulation factors, PiCT, ROTEM, multiplate", 
            "measure": "Evaluation of the effect of RXA on coagulation assays in time", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "source": "Luzerner Kantonsspital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Research Foundation of the Division of Hematology, Luzerner Kantonsspital, Switzerland", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Bayer (Schweiz) AG, Switzerland", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Prof. Dr. Dr. med. Walter A. Wuillemin, MD, PhD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "August 2013"
    }
}